PreveCeutical Medical Inc.
PRVCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.07 | -0.02 | 0.44 |
| FCF Yield | -2.78% | -2.90% | -1.32% | -0.47% |
| EV / EBITDA | -29.99 | -20.45 | -24.92 | -118.41 |
| Quality | ||||
| ROIC | 27.59% | 45.99% | 25.75% | 7.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.64 | 0.45 | 0.14 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 33.65% | -248.04% | -142.87% | 40.45% |
| Safety | ||||
| Net Debt / EBITDA | -5.80 | -3.88 | -6.77 | -28.01 |
| Interest Coverage | -9.60 | -15.13 | -8.22 | -1.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -31,571.97 | 0.00 | 0.00 |